This Biopharmaceutical Company Expands Its Out-Licensing Deal For Pancreatic Cancer Patients

Can-Fite BioPharma Expands Out-Licensing Deal with Ewopharma: A New Hope for Pancreatic Cancer Patients.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant development, Can-Fite BioPharma Ltd. (NYSE: CANF), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, has re…